jiaoti huang, m - ucla healthpathology.ucla.edu/workfiles/clinical...

CV Date: February 26, 2015

Jiaoti Huang, M.D., Ph.D.

Professor of Pathology and Urology

Frances and Albert Piansky Endowed Chair

Chief of Surgical Pathology

Director of Urologic Pathology

Departments of Pathology & Urology

David Geffen School of Medicine at UCLA

650 Charles E. Young Drive South, 13-226 CHS

Los Angeles, CA 90095-1732

Phone: 310-267-2264

E-mail: [email protected]

Education:

M.D. Anhui Medical University, Hefei, China, 09/78-08/83

M.S. Institute of Radiation Medicine, Beijing, China, 09/83-08/86

Ph.D. New York University School of Medicine, New York, NY, 09/87-08/91

Research Training:

1. Graduate Program, Institute of Radiation Medicine, Beijing, China, 09/83-08/86

2. Ph.D. Program, Molecular and Cellular Biology, New York University School of Medicine,

New York, NY, 09/87-08/91

3. Leukemia Society of America Postdoctoral Fellow, Department of Pharmacology, New York

University School of Medicine, New York, NY, 09/91-11/94

4. Leukemia Society of America Postdoctoral Fellow, Dept of Medicine, Yale University

School of Medicine, New Haven, CT, 12/94-06/95

Clinical Training:

Residency Anatomic and Clinical Pathology Residency Program, New York

University Medical Center, New York, NY, 07/95-06/99

Chief Residency Department of Pathology, New York University Medical Center, New

York, NY 07/98-06/99

Fellowship Oncologic Surgical Pathology Fellowship Program, Department of

Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY,

07/99-06/00

Leadership Training

Completed the course “Leadership Development for Physicians in Academic Health Centers”,

November 2-14, 2014. Harvard School of Public Health

Academic Appointments:

1. Assistant Professor, Department of Pathology and Laboratory Medicine, University of

Rochester Medical Center, Rochester, NY, July 2000-Sept 2005

2. Associate Professor, Department of Pathology and Laboratory Medicine, University of

Rochester Medical Center, Rochester, NY, Oct 2005-2007

3. Associate Professor of Oncology, James P. Wilmot Cancer Center, University of

Rochester Medical Center, Rochester, NY, Oct 2006-2007

4. Associate Professor of Urology, Department of Urology, University of Rochester

Medical Center, Rochester, NY, Oct 2006-2007 5. Professor of Pathology, Urology and Oncology, University of Rochester Medical Center,

Rochester, NY, Feb 2008-Aug. 2008

6. Co-Director, Genitourinary Pathology Fellowship Program, Department of Pathology and

Laboratory Medicine, University of Rochester Medical Center, July 2002-Aug. 2008

7. Adjunct Professor, Department of Pathology and Laboratory Medicine, University of

Rochester Medical Center, Sept. 2008-2010 8. Professor and Director of Urologic Pathology, Department of Pathology and Laboratory

Medicine, UCLA David Geffen School of Medicine, Sept. 2008-present

9. Chief of Surgical Pathology, Department of Pathology and Laboratory Medicine, UCLA

David Geffen School of Medicine, June. 2013-present

10. Professor of Urology, UCLA David Geffen School of Medicine, Sept. 2009-present

11. Co-Director, Pathway Pathology Laboratory, UCLA Institute of Molecular Medicine

(IMED), June 2009-present

12. Member, UCLA Broad Center of Regenerative Medicine and Stem Cell Research, Oct

2009-present

13. Member, UCLA Jonsson Comprehensive Cancer Center, January 2010-present

Hospital Appointments:

1. Attending Pathologist, Strong Memorial Hospital, University of Rochester, July 2000-

2008

2. Director, Clinical Immunohistochemistry Laboratory, Department of Pathology and

Laboratory Medicine, University of Rochester Medical Center, July 2003-2008

3. Attending Pathologist, UCLA Ronald Reagan Medical Center, Sept. 2008-present

4. Director of Urologic Pathology, UCLA Ronald Reagan Medical Center, Sept. 2008-

present

5. Chief of Surgical Pathology, Department of Pathology and Laboratory Medicine, UCLA

David Geffen School of Medicine, June. 2013-present

Other Appointments:

1. Staff Scientist, Institute of Radiation Medicine, Beijing, China, 09/86-08/87

2. Consultant Pathologist, ImPath, Inc., New York, NY, 07/99-06/00

3. Member, Scientific Advisory Board, Egenix, Inc., 10/02-present

4. Chair, Scientific advisory Board, Egenix, Inc., 06/04-06/08

5. Deputy Chair, Scientific advisory Board, Egenix, Inc., 06/08-present

6. Visiting Professor, Anhui Medical University, China, August 2009-present

7. Visiting Professor, Peking University Wu Jieping Urologic Center, May 2011-present

8. Consultant, Verve Medical Inc., May 2012 – present

9. Consultant, Micatu Inc., July 2012 - present

Study Sections:

1. Study Section Member, Department of Defense Prostate Cancer Research Program, 2003.

2. Study Section Member, J&J Discovery Fund, University of Rochester, 2005, 2006

3. Scientific Reviewer, Roy J. Carver Charitable Trust, December 2006

4. Scientific Reviewer, Laboratory Support Center, Clinical and Translation Science

Institute (CTSI), University of Rochester, 2007

5. Study Section Member, SPORE applications in Prostate, Breast and Skin cancers,

National Cancer Institute, February 2007

6. Scientific Reviewer, Head and Neck SPORE supplement funds, National Cancer

Institute, May 2007

7. Study Section Member, Department of Defense Prostate Cancer Research Program, 2007

8. Study Section Member, Department of Defense Breast Cancer Research Program, 2008

9. Study Section Member, SPORE in Prostate, Ovarian, Pancreatic and Gastrointestinal

Cancers, National Cancer Institute, 2008

10. Scientific Reviewer, The Prostate Cancer Research Foundation, London, 2008

11. Study Section Member, SPORE in Skin and Prostate Cancers, National Cancer Institute,

2010

12. Study Section Member, Department of Defense Prostate Cancer Research Program, 2011

13. Review panel member, Fellowship Awards for Outstanding Students Studying Abroad,

Minister of Education of China, Dec 2011

14. Reviewer, the Williams Barker Bequest for research into cancer (2011/2012), the

Medical Research Foundation of the Medical Research Council (MRC), UK, January

2012

15. Online reviewer, Department of Defence Prostate Cancer Research Program (Detection,

Diagnosis and Prognosis), May 2012

16. Study section member, Cancer Group 4, National Natural Science Foundation of China,

July 2012

17. Study section member, Department of Defence Prostate Cancer Research Program,

Clinical and Experimental Therapeutics (CET-1) panel, October 2012

18. Study section member, 2013 Department of Defence Prostate Cancer Research Program,

Pre-application-Clinical and Experimental Therapeutics-2, PRE-CET-2


Exploration-Hypothesis Development-Clinical and Experimental Therapeutics-1 - Online

Reviewer

20. Study section member, Cancer Group 5, National Natural Science Foundation of China,

July 2013

https://p2rmis.com/index.cfm?fuseaction=Program_Registration.home&tabfuse=pif&tab_id=1&panel_id=2953&modid=20&modlevel=1&fy=2013&program=PCRP&prg_part_id=67563&part_type=OR&Client=USAMRMC&startPage=1&mmPath=0




Exploration-Hypothesis Development-Clinical and Experimental Therapeutics-2 - Online

Reviewer


Clinical and Experimental Therapeutics-2, PRE-CET-2

23. Online Reviewer, Special Emphasis Grants, China Natural Science Foundation, May

2014

24. Study section member, Special Emphasis Grants, National Natural Science Foundation

of China, July 2014

25. Study section member, General Grants, National Natural Science Foundation of China,

July 2014

26. Judge, State Natural Science Award of the People's Republic of China, June 2014


EHD-CET2 peer review panel, August 2014

28. Study section member, Prostate Cancer Foundation Challenge Award, October 2014


CET2 peer review panel, November 2014

30. Study section chair, 2014 Department of Defence Prostate Cancer Research Program,

Biospecimen Resource Site panel, December 2014

31. Ad Hoc study section member, NIH Cancer Biomarkers Study Section (CBSS), February,

2015

32. Study section member for NIH Special Emphasis Panel “Molecular and Cellular

Characterization of Screen-Detected Lesions” (UO1). April, 2015

Services in Professional Organizations:

1. Committee Member for Stipend Award, International Society of Urologic Pathology,

2008-2010

2. Cadre Leader for Genitourinary Pathology, The Cancer and Leukemia Group B (a

national clinical trial group sponsored by the National Cancer Institute), 2010-2011

3. Cadre Leader, Genitourinary Pathology, Alliance for Clinical Trials in Oncology, 2011-

present

4. Co-Chair, Prostate Cancer Foundation-China Initiative, Prostate Cancer Foundation,

October 2011-present

5. Judge, Excellence in GU Pathology Awards, United States & Canadian Academy of

Pathology and International Society of Urologic Pathology, 2013

6. Member of the Prostate Cancer Foundation Research Awards Standing Review

Committee, 2013-present

Meetings Organized

1. First Annual Scientific Symposium of Prostate Cancer Foundation-China, March 2012,

Beijing, China

2. Second Annual Scientific Symposium of Prostate Cancer Foundation-China, May 2013,

Shanghai, China




http://www.cancer.gov/

CME Courses

1. Faculty, “State of Art of Urology”, Marina del Ray, CA, March 2014

2. Faculty, “The Evolving Role of MRI in Prostate Cancer Management: Detection, Staging,

Surveillance, Follow Up, and Reporting”. Santa Monica, CA, February 2015

Other Services:

1. Member, Residency Education Committee, UCLA Pathology and Laboratory Medicine,

2008-present

2. Expert Reviewer, China Ministry of Education Scholarship Committee, 2011-present

3. Member, Academic Personnel Committee, UCLA Pathology and Laboratory Medicine,

2011-2012

4. Chair, Academic Personnel Committee, UCLA Pathology and Laboratory Medicine,

2012-2013

5. Moderator, 2013 Amgen Scholars Program U.S. Symposium, Los Angeles, CA. July 20,

2013.

6. Chair of Search Committee for a neuropathologist, 2014-2015

Areas of Clinical Expertise:

1. Genitourinary Pathology

2. Gynecological Pathology

3. General Surgical Pathology

4. Oncologic Surgical Pathology

5. Immunohistochemistry

Areas of Research Interests:

1. Neuroendocrine differentiation of prostate cancer and its role in disease progression

2. Novel biomarkers of prostate cancer

3. Novel therapeutics of prostate cancer targeting multiple signaling pathways

4. Improving imaging, biopsy and surgical planning for prostate cancer

Editorial Boards and Journal Reviewers:

1. Editorial Board Member, Prostate Cancer and Prostate Diseases, 08/01/12-present

2. Member, Overseas Editorial Board, Chinese Journal of Pathology, 07/01/12-present

3. Associate Editor, Chinese Journal of Pathology, 10/01/14-present

4. Member, Overseas Editorial Board, Journal of Clinical and Experimental Pathology,

07/05-present

5. Editorial Board Member, Asian Journal of Andrology, 04/2007-present

6. Senior Editorial Board Member, American Journal of Translational Research, 2009-

present

7. Senior Editorial Board Member, American Journal of Cancer Research, 2010-present

8. Executive Editorial Board Member, International Journal of Clinical and Experimental

Pathology, 04/2007-present

9. Editorial Board Member, Analytic and Quantitative Cytology and Histology, 03/2007-

present

10. Editorial Board Member, The Open Prostate Cancer Journal, 09/08-present

11. Editorial Board Member, Chinese Journal of Urology, 09/10-present

12. Senior Editorial Board Member, Journal of Cancer Therapeutics and Research. 11/11-

present

13. Journal reviewer for: Cancer Research, Clinical Cancer Research, Prostate, Applied

Immunohistochemistry and Molecular Morphology, Asian Journal of Andrology,

American Journal of Pathology, Archives of Pathology and Laboratory Medicine,

Analytical and Quantitative Cytology and Histology, PloS Medicine, Human Pathology,

International Journal of Clinical and Experimental Pathology, British Journal of Cancer,

Endocrine-Related Cancer, Journal of Cellular and Molecular Medicine, Endocrinology,

Journal of Anatomy, Oncogene, Genes and Cancer, Prostate Cancer and Prostatic

Diseases, The Open Prostate Journal, BMC Urology, Journal of Thoracic Oncology, BMJ

Case Reports, Journal of Cancer Science and Therapy, International Journal of Cancer,

International Journal of Biologic Sciences, , Journal of Cancer Therapeutics and

Research, Cancer Biomarkers, Cell Cycle, Molecular Cancer Therapeutics, Cancer,

Biomed Central Genomics, International Journal of Urology, Journal of Urology, Cancer

Letters, PNAS

Professional Memberships:

1. United States and Canadian Academy of Pathology

2. American Association for Cancer Research

3. International Society of Genitourinary Pathology

4. Chinese American Pathologists Association (life-time member)

5. The Chinese Biological Investigators Society (life-time member)

Mentoring Highlights:

1. Graduate students, postdoctoral fellows, and residents of pathology and urology (over

100)

2. Fellows of Genitourinary Pathology (7 to date)

3. Jason Wang (was South Pasadena High School student while working in my lab.

Currently an undergraduate student at Stanford University) was National Semifinalist

for 2013 Siemens Competition (Math : Science : Technology) and 2014 The Intel

Science Talent Search (Intel STS) (My role: Mentor).

4. Alice Soragli won 2014 AACR-Millennium Fellowship in Prostate Cancer Research

(My role: co-mentor)

Licensure:

Full unrestricted medical license in the States of New York (License #: 211805, currently

inactive) and California (License #: 53385)

Board Certification:

Diplomat of American Board of Pathology, Combined Anatomic and Clinical Pathology,

2000 (no expiration)

Honors and Awards:

1. China-US Biochemistry and Molecular Biology Examination Application (CUSBEA,

1987)

2. Leukemia Society of America Postdoctoral Fellowship ($75,000) (1992-1995)

3. Scientific Exchange Award, Leukemia Society of America ($5,000) (1993)

4. Eric A. Schenk Award for Excellence in Pathology Education, University of Rochester

Medical Center (Once a year, voted by pathology residents and fellows), 2006

5. Roberta Nieberg Faculty Teaching Award, UCLA Pathology and Laboratory Medicine

(Once a year, voted by pathology residents and fellows), 2008

6. Visiting Professor, Department of Urology, Massachusetts General Hospital of Harvard

University, June 2011

7. Frances and Albert Piansky Endowed Chair, UCLA Department of Pathology and

Laboratory Medicine, November, 2014-present

Grant Support

Finished grants:

1. Epigen Inc., “Expression of HCA protein in prostate cancer”.

Direct cost of $10,950 and 25% indirect cost (2002-2003)

Role: Principal Investigator

2. Epigen Inc., “Expression of HCA protein in metastatic prostate cancer”.

Direct cost of $20,000 and 25% indirect cost (2003-2005)


3. R21 DK063126 “Inducible Gene Expression in Mouse Urothelium” (PI: Jay E. Reeder)

Agency: NIH

Period: Aug-01-2003 - Jul-01-2005

Award total: $315,000

%Effort: 5%

Role: co-Principal Investigator

4. Laboratory Support Fund “Targeting neuroendocrine cells of prostate cancer”

University of Rochester Clinical and Translation Science Institute

Role: PI

Period: 2008


5. “RAD001 inhibition of neuroendocrine differentiation in prostate cancer”

Novatis Pharmaceuticals

Role: PI

Period: 2007-2008

Award total: $4,200

6 Translational Research Funds, UCLA Department of Pathology (PI: Clebanoff)

Period: 01/01/10 – 05/31/10

Title: Gene Profiling Studies to Identify molecular changes in pre-malignant prostate

tissue”

Award Total: $8,000

Role: Faculty Sponsor

7. Department of Defense Prostate Cancer Research Program PC061456 (PI: Huang)

Period: 1/1/2007 – 7/31/2010

Title: The Function of PTP1B in Neuroendocrine Differentiation of Prostate Cancer (PI:

Huang)


Percent effort: 20%


8 American Cancer Society RSG-07-092-01-TBE (PI: Huang)

Period: 1/1/2007 – 12/31/2010

Title: Neuroendocrine Differentiation and IL-8 Signaling in Prostate Cancer (PI: Huang)

Overall goals of the project: To study whether neuroendocrine differentiation and IL-8

signaling contribute to the progression of prostate cancer to the androgen-independent

state, using both cell culture models and human tissue.


Direct cost: $200,000/yr

Percent effort: 40%


9. Development Research Award from UCLA Prostate Cancer SPORE (PI: Huang)

Period: 2/1/2009-1/31/2011

Title: Targeting Neuroendocrine Cells of Prostate Cancer

Overall goals of the project: To study if the elimination of neuroendocrine cells in mouse

prostate cancer models may delay the development and progression of prostate cancer



10 UCLA Research Services Research Fund (PI: Huang)

Period: 5/1/2010 – 12/31/2010

Title: Gene Profiling Studies to Identify Molecular Changes in Basal, Luminal and

Stromal Cells of Pre-Cancerous Prostate Tissue

Overall goals of the project: To identify molecular alterations that represent early or pre-

cancerous stage in luminal, basal and stromal cells of the prostate



11 Postate Cancer Foundation Challenge Award (PI: Witte)

Period: 6/1/2008-5/30/2012

Title: Defining Targets and Biomarkers in Prostate Cancer Stem Cells: New Therapeutic

Opportunities


Role: Co-PI

12. Prostate Cancer Foundation Creativity Award (PI: Rettig)

Period: 5/1/2010-4/30/2012

Title: A Nano-Structured Platform for Enhanced Detection of CTCs in Prostate Cancer

Patients

Overall goals of the project: To detect and characterize circulating tumor cells in prostate

cancer patients for the purpose of prognosis and targeted therapy


Role: Co-PI

14. Cal-Tech-UCLA Joint Center for Translational Medicine Program (PI: Huang)

Period: 6/1/2011 – 5/31/2012

Title: Biomarkers for prostate cancer

Direct cost: $50,000


14. Translational Research Funds, UCLA Department of Pathology (PI: Kerkoutian)

Period: 10/01/11 – 09/31/12

Title: Predicting the Aggressiveness of Prostate Cancer on Biopsy

Award Total: $20,000

Role: Faculty Sponsor

15. NIH 1R01CA158627-01 (PI: Leonard Marks)

Period: 07/05/2011 – 06/30/2014

Title: Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the

Prostate

Direct Cost: $487,849

Percent effort: 5%

Role: co-PI

Current grants:

1 1R01CA181242-01A1 (Chao, PI)

Period: 1/2/2015 – 12/31/2019

Title: The identification of DNA methylation markers for risk of metastasis in localized

prostate cancer

Direct cost: $1,037,500 (all 5 years)

Percent effort: 5%

Role: Co-Investigator

2. Department of Defense Prostate Cancer Research Program (Idea Development Award)

W81XWH-11-1-0227 (PI: Jiaoti Huang)

Period: 4/1/2011 – 3/31/2015

Title: The Function of Neuroendocrine Cells in Prostate Cancer


Percent effort: 10%


3 Department of Defense Prostate Cancer Research Program W81XWH-12-1-0206 (PI:

Lily Wu)

Period: 07/01/2012 – 06/30/2015

Title: Disrupting the Pro-Tumorigenic Influences of Tumor-Infiltrating Myeloid Cells by

CSF1R Blockade to Augment Androgen Deprivation Therapy in Prostate Cancer


Percentage effort: 3%

Role: co-PI

4. Stand–up-to-Cancer Dream Team Award (PI: Eric Small and Owen Witte)

Period: 1/01/2013 -12/31/2015

Title: Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer

Direct Cost: $10,000,000 (all 3 years)


Role: Pathologist

5. Prostate Cancer Foundation Honorable A. David Mazzone Special Challenge Award (PI:

Robert Reiter)

Period: 01/01/2013 – 12/31/2015

Title: Preventing Treatment Resistance by Co-Targeting Androgen Receptor and

SRC/MEK1-Dependent Epithelial to Mesenchymal Transition

Direct Cost: $2,000,000 (all 3 years)

Percent effort: 5%

Role: Co-PI and Pathologist

6. National Cancer Institute 1R01CA172603-01A1 (PI: Jiaoti Huang)

Period: 07/01/2013 – 6/30/2018

Title: A Novel Strategy to Identify Prostate Cancer Biomarkers for Patient Management


Percent effort: 20%

Role: Principle Investigator

http://www.standup2cancer.org/dream_teams/view/targeting_adaptive_pathways_in_metastatic_crpc

7. Jonsson Comprehensive Cancer Center Impact Grant (PI: Sanaz Memarzadeh)

Period: 10/1/14-9/30/15

Title: Restoration of p53 function with a novel structure-based peptide in therapy of solid

tumors

Direct cost: $200,000

Percent effort: 3%

Role: co-Principle Investigator

8. UCLA SPORE in Prostate Cancer (2P50CA092131-11A1) (PI: Robert Reiter)

Period: 1/7/2001 – 6/30/2018

Direct cost: $2,300,000/yr


Role: Co-Director, Tissue Core

9. National Cancer Institute 1R01CA158627-01 (Marks, PI)

Period: 07/01/2012 – 06/30/2015

Title: Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the

Prostate


Percent effort: 3%

Role: Co-Investigator

Publications:

1. Huang J. and Tang Z. Measurement of estrogen receptor in the nuclei of bone marrow cells

of male mice after the administration of estrogen. Bulletin Acad Mil Med Sci 1988; 2:24-26

2. Dolph PJ, Huang J, Schneider RJ. Translation by the adenovirus tripartite leader: elements

which determine independence from cap-binding protein complex. J Virol 1990; 64:2669-

77

3. Huang J, Schneider RJ. Adenovirus inhibition of cellular protein synthesis is prevented by

the drug 2-aminopurine. Proc Natl Acad Sci U S A 1990; 87:18 7115-9

4. Huang J, Schneider RJ. Adenovirus inhibition of cellular protein synthesis involves

inactivation of cap-binding protein. Cell 1991; 65:271-80

5. Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM, Huang J,

Cannizzaro LA, Park SH, Druck T, Huebner K, Barnea G, Sap J, and Schlessinger J. The

cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous

system. J Biol Chem 1993; 268:10573-81

6. Vogel W, Lammers R, Huang J, Ullrich A Activation of a phosphotyrosine phosphatase by

tyrosine phosphorylation. Science 1993; 259:1611-4

7. Sorokin A, Mohammadi M, Huang J, Schlessinger J. Internalization of fibroblast growth

factor receptor is inhibited by a point mutation at tyrosine 766. J Biol Chem 1994;

269:17056-61

8. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M,

Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is

responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994;

79:1015-24

9. Huang J, Mohammadi M, Rodrigues GA, Schlessinger J. Reduced activation of RAF-1 and

MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of

phosphatidylinositol hydrolysis. J Biol Chem 1995; 270:5065-72

10. Trachman JD, Huang J and Reem GH. Activation of human thymocytes induces the

phosphorylation of protein tyrosine phosphatase 1C. C. R. Acad Sci Paris de la vie/Life

Sciences 1995;318:367-74

11. Saric M, Applebaum RM, Culliford AT, Huang J, Scholes JV, Kronzon I. Massive Atrial

Septal Lipomatous Hypertrophy. Echocardiography 1999; 16: 833–834

12. Gu M, Shi W, Huang J, Barakat, RR, Thaler HT and Saigo PE. Association between initial

diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with

endometrial carcinoma. Cancer (Cancer Cytopathology) 2000;90:143-7

13. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous

and metachronous tumors of the lung: Impact on management and prognosis. Ann Diagn

Pathol 2001;5:321-329

14. Huang J, Behrens C, Wistuba II, Gazdar AF, and Jagirdar, J. Clonality of combined tumors:

A molecular genetic study. Arch Pathol Lab Med 2002; 126: 437–441

15. Huang J and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate Cancer: An

Overview. in Advances in Oncology: The Expanding Role of Octreotide I. Page 243-262.

Ed. SWJ Lamberts and L Dogliotti. BioScientifica Ltd, Bristol, UK 2002

16. Liu Z, Huang J, Yan, Z and Tan, J: Application of flow cytometry in the diagnosis and

differential disgnosis of lymphoma and leukemia. Chinese J Path 2002; 31:352-353

17. Lee Y-F, Lin W-J, Huang J, Messing EM, Chan FL, Wilding G, and Chang C. Activation of

Mitogen-activated Protein Kinase Pathway by the Antiandrogen Hydroxyflutamide in

Androgen Receptor-negative Prostate Cancer Cells. Cancer Res 2002; 62:6039-6042

18. Ni J, Chen M, Zhang Y, Li R, Huang J and Yeh S. Vitamin E sccinate inhibits human

prostate cancer cell growth via modulating cell cycle regulatory machinery Biochem

Biophys Res Commun 2003; 300:357-63

19. Chen TS, McNully M, Hulbert W, di Sant’agnese and Huang J. Renal oncocytosis

presenting in childhood. A Case Report Intl J Surg Pathol 2003; 11:325-329

20. Daiss J, Carney J, Cartun R, Codington J, Erdrich C, Hinchman C, Huang J, Mauck J. and

Schnipelsky P. Human Carcinoma Antigen: A Marker Useful for Discriminating between

Benign Prostatic Hyperplasia and Prostate Cancer. J. Clinical Ligand Assay 2003; 26: 177-

180.

21. Li R, Yao JL, Bourne PA, di Sant’agnese PA and Huang J. Frequent expression of human

carcinoma-associated antigen (HCA), a mucin-type glycoprotein, by cells of prostatic

carcinoma. Arch Path Lab Med. 2004; 128: 1412-1417

22. Patton KT, Tretiakova MS, Yao JL, Papavero V, Huo L, Adley BP, Wu G, Huang J, Pins

MR, Teh BT and Yang XJ. Expression of RON proto-oncogene in renal oncocytoma and

chromophobe renal cell carcinoma. Amer. J. Surg. Pathol. 2004; 28:1045-50

23. Yao JL, Bourne PA, Yang Q, di Sant’Agnese PA and Huang J. Overexpression of Human

Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder. Arch Path

Lab Med. 2004;128:785–787

24. Hu Y-C, Yeh S-Y, Yeh S-D, Sampson EK, Li P, Hsu C-L, Ting H-J, Lin H-K, Wang L, Kim

Y, Huang J, and Chang C. Functional Domain and Motif Analyses of Androgen Receptor

Coregulator ARA70 and Its Differential Expression in Prostate Cancer. J Biol Chem 2004;

279:33438-46

25. Liang S, Yao JL, Bourne PA, di Sant’Agnese PA, Huang J and Lei J. Over-Expression of

Human Carcinoma-Associated Antigen in Esophageal Adenocarcinoma and its Precursor

Lesions. Amer J Clin Pathol 2004;122:747-51

26. Li R, Ni J, Yeh S, Bourne PA, Yao J, di Sant’agnese PA and Huang J. Cell culture block

array for immunocytochemical study of protein expression in cultured cells. Applied

Immunohistochemistry and Molecular Morphology 2005; 13:85-90

27. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant’Agnese PA and Reeder JE.

Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non-

neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166:1807-1815

28. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY.

Overexpression of Decoy receptor 3 in precancerous lesions and adenocarcinoma of the

esophagus. Amer J Clin Pathol 2005; 124:282-7 29. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by

synovial sarcoma oncoprotein SYT-SSX1. Oncogene. 2006; 25:1042-52

30. Huang J, Wu C, Yao JL and di Sant’Agnese PA. Neuroendocrine differentiation in prostate

cancer. Proceedings of the 4th Asian-Pacific International Academy of Pathology Congress.

Page 57-61. Ed. Wu BQ. Medimond S.r.l.. Bologna, Italy 2005

31. Huang J, Yao JL and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate

Cancer. In Prostate Cancer: Principles and Practice. Page 143-150. Ed Kirby R, Partin AW,

Feneley M, Parsons JK. Martin Dunitz Ltd (Taylor & Francis Group), London, UK 2005

32. Lei J., Bourne PA, di Sant’Agnese PA and Huang J. Cytoplasmic staining of TTF-1 in the

differential diagnosis of hepatocellular carcinoma versus cholangiocarcinoma and metastatic

carcinoma of the liver. Amer J. Clin Pathol 2006;125:519-525.

33. Wu C, Zhang L, Bourne PA, Reeder JE, di Sant’Agnese PA, Yao JL, Na Y and Huang J.

Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate

cancer. Prostate 2006; 66:1125-1135 .

34. Yao JL, Madeb R, Bourne PA, Lei J, Yang X, Tickoo, S, Liu Z, Tan D, Cheng L, Hatem F,

Huang J, and di Sant’Agnese PA. Small cell carcinoma of the prostate: an

immunohistochemical study. Am J Surg Pathol 2006; 30:705-12.

35. Huang J, Yao JL, di Sant’Agnese PA, Yang Q, Bourne PA, and Na Y.

Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate

2006; 66:1399-406.

36. Johnson A, Conover D, Huang J, Messing ME, Ning R, O'Connell M, Rossi M, Sun T, Wu

X and Reeder JE. Early Detection and Measurement of Urothelial Tumors in Mice. Urology

2006; 67:1309-14

37. Zhang Z, Rosen DG, Yao JL, Huang J, Liu J. Expression of p14(ARF), p15(INK4b),

p16(INK4a), and DCR2 increases during prostate cancer progression. Mod Pathol. 2006;

19:1339-43

38. Wu C, Yao JL, di Sant’Agnese PA, Na Y, and Huang J. Neuroendocrine differentiation in

prostate cancer. Chinese J Pathol 2006; 35 (9): 565-567

39. Wagner DG, Joseph J, Huang J and Xu H. Malakoplakia of the prostate on needle core

biopsy: A case report and review of the literature. Int. J. Surg. Pathol. 2006 15:86-9

40. Markhardt KB, Rubens DJ, Huang J and Dogra VS. Sonographic features of Biliary

Hamartomas with histopathological correlation. Journal of Ultrasound in Medicine 2006;

25:1631-3

41. Huang J, Wu C, di Sant’Agnese PA, Yao JL, Cheng L and Na Y. Function and molecular

mechanisms of neuroendocrine cells in prostate cancer. Anal Quanti Cytol Histol 2007; 29:

128-138 42. Wagner DG, Yao JL, di Sant’Agnese PA, Cheng L, Lopez-Beltran A, Montironi R and

Huang J. Soft tissue tumors in the prostate. Anal Quanti Cytol Histol 2007;29:341–350

43. Bhatt S, Huang J and Dogra VS. Littoral cell angioma of spleen: Radiologic-pathologic

correlation. Am J Roentgenology 2007;188(5):1365-6

44. Oh WK, Tay MH and Huang J. Is There A Role For Platinum Chemotherapy In

The Treatment Of Patients With Hormone-Refractory Prostate Cancer? Cancer 2007;

109(3):477-86

45. Liang JJ, Wang Z, Chiriboga L, Greco MA, Shapiro E, Huang H, Yang XJ, Huang J, Peng

Y, Melamed J, Garabedian M, Lee P. The expression and function of androgen receptor

coactivator p44 and protein arginine methyltransfersase 5 (PRMT5) in the developing testis

and testicular tumors. J. Urol. 2007; 177(5):1918-22

46. Wu C, and Huang J. PI3 kinase-AKT-mTOR pathway is involved in neuroendocrine

differentiation of prostate cancer. J. Biol. Chem. 2007; 282(6):3571-83

47. Wu C, Chen G, Na Y, Xin D, Yao JL, di Sant’Agnese PA and Huang J. The function of

Interleukin-8 in prostate cancer. In Progress in Chemokine Research. Eds Linkes WP.

Nova Science Publishers, Inc. New York, 2007. pp149-156.

48. Yao JL, Huang J and di Sant’Agnese PA. Small Cell Carcinoma of the Prostate. Diagnostic

Histopathology. 2008; 14/3: 117-121

49. Cheng L, Zhang S, Wang M, Davidson DD, Morton MJ, Huang J, Zheng S, Jones TD, Beck

SD, Foster RS: Molecular Genetic Evidence Supporting the Neoplastic Nature of Stromal

Cells in “Fibrosis” After Chemotherapy for Testicular Germ Cell Tumors. J Pathol 2007:

213: 65-71

50. Podder TK, Sherman J, Li L, Joseph J, Rubens DR, Messing EM, Huang J and Yu Y.

Mechanical properties of human prostate tissue in the context of surgical needle insertion.

Int. J. Computer Assisted Radiology and Surgery 2007; 2 (Suppl I):S106-S108

51. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin M-E, Ryan C, Huang J and Oh WK for

the Prostate Cancer Clinical Trials Consortium (PCCTC). A Phase II study of carboplatin

plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory

to docetaxel. Cancer 2008; 112:521-6 52. Hui P, Wang HL, Chu P, Yang B, Huang J, Baergen RN, Sklar J, Yang XJ, Soslow RA.

Absence of Y chromosome in human placental site trophoblastic tumor. Mod Pathol. 2007;

20:1055-60 53. Li

L, Yao

JL, di Sant’Agnese PA, Bourne PA, Picken MM, Young AN, Shen SS

and Huang

J. Expression of Claudin-7 in Benign Kidney and Kidney Tumors. Intl. J. Clin. Exp.

Pathol. 2008; 1:57-64

54. Simon RA, di Sant’Agnese PA, Palapattu GS, Singer ea, Candelario gd, Huang J and Yao

JL. Mucinous Tubular and Spindle Cell Carcinoma of the Kidney with Sarcomatoid

Differentiation Intl. J. Clin. Exp. Pathol. 2008; 1:180-184

55. Johnson AM, O’Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder

JE. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of

bladder cancer: a role for thrombospondin-1. BMC Urology 2008; 8:7

56. Li L, Xu H, Spalding BO, Cheng L, Simon R, Yao JL, di Sant’Agnese PA, Bourne PA and

Huang J. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and

urothelial tumors. Hum Pathol 2008; 39:1205-11

57. Cai Y, Lee Y-F, Li G, Liu S, Bao B-Y, Huang J, Hsu CL and Chang C. A new prostate

cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J.

Can. 2008; 123:195-201

58. Gobbo S, Eble JN, Huang J, Grignon DJ, Wang M, Martignoni G, Brunelli M, Cheng L:

Schwannoma of the kidney. Mod Pathol 2008; 21:779-83

59. Lei JL, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of

hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2008; 2:151-159

60. Liu B, Yu H-M I, Huang J, Hsu w. Co-opted Jnk/Sapk signaling in Wnt/b-catenin-induced

tumorigenesis. Neoplasia 2008; 10: 1004-1013

61. Deng X, Liu H, Huang J, Cheng L, Keller E, Parsons S and Hu C. Ionizing radiation induces

prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2:

Implications for disease progression. Cancer Research 2008;68:9663-70

62. Simon RA, di Sant'Agnese PA, Huang L-S, Xu H, Yao JL, Yang Q, Liang S, Liu, J, Lee R,

Cheng L, Oh WK, Palapattu G, Wei J, and Huang J. CD44 Expression is a Feature of

Prostatic Small Cell Carcinoma and Distinguishes it from its Mimickers. Hum Pathol

2009;40:252-8

63. Wagner DG and Huang J. Small Cell Carcinoma of the Prostate. eMedicine from WebMD.

Updated April 20, 2009. Available at: http://emedicine.medscape.com/article/1611899-

overview.

64. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang

L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem

cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009

15;69:787-98

65. Sun Y, Niu J and Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl

Res 2009: 1:148-162

66. Huang J, Lee P, Mikami Y, Melamed J. Dysplastic ("in-situ") Lesions in multifocal renal

oncocytomas (oncocytosis). Int J Clin Exp Pathol. 2009;2:583-7.

67. Huang J and Witte ON. A Seminal Finding for Prostate Cancer? New Eng. J. Med. 2010;

362: 175-6

68. Yuan P, Kadara H, Behrens C, Tang XM, Woods D, Solis LM, Huang J, Spinola M, Dong

W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD

and Wistuba

II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed

in the pathogenesis of squamous cell carcinomas of the lung. PLoS ONE. 2010; 5(2): e9112

69. Lawson DA, Zong Z, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells

are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010; 107:

2610-5

70. Shen P, Wei W, Yang X, Zeng H, Li X, Yang J, Wang J, Huang J. The influence of

percutaneous nephrolithotomy on human systemic stress response, SIRS and renal function.

Urol Res. 2010 Mar 4. [Epub ahead of print]

71. Marks LS and Huang J. Re: Copy number analysis indicates monoclonal origin of lethal

metastatic Prostate cancer. Words of Wisdom article. Eur. J. Urol. 2010; 57: 727-8

72. Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS A novel in

vitro assay of human prostate cancer tumor initiation. Prostate 2010; 70:1379-87

73. Brick A, Niu J, Huang J and Oh WK. Possibility for Platinum Chemotherapy Treatment for

HRPC Patients? In Drug Management of Prostate Cancer. Eds Figg WD, Chau CH, Small

EJ. Chapter 14, pp 153-61. Humana Press, NJ, 2010

74. Ward SC, Huang J, Tickoo S, Thung SN, Ladanyi, M and Klimstra DS. Fibrolamellar

carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile

duct differentiation. Modern Pathol 2010 23:1180-90

75. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell-of-origin for

human prostate cancer. Science 2010;329:568-71.

76. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin

SH, Mills GB, Liu J. CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell

Cycle, Diminished Apoptosis, and Enhanced Angiogenesis. Clin Cancer Res. 2010; 16:

3875-86

77. Fang F, Christian WV, Gorman SG, Cui M, Huang J, Tieu K, and Ballatori N. Neurosteroid

transport by the organic solute transporter OSTα-OSTβ. J Neurochemistry 2010;115:220-33

78. Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, Schafenacker AM,

Huang J, Witte ON. Cell-autonomous activation of the PI3-kinase pathway initiates

endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A. 2010; 107:

17298-303

79. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Ladan F, Wada R,

Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, invasion,

metastasis and castration resistance. Nat Med 2010; 16:1414-20 PMID: 21057494

80. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin

Expression in Prostate: A Novel Finding. Cancer Investigation. 2011; 29:62-67

81. Sun Y and Huang J. Novel genetic loci associated with prostate cancer in the Japanese

population. (Research Highlight Article) Asian J. Androl. 2010; 13:120-1

82. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J and Li L-C.

Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated

overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer

Res 2010; 70:10182-91.

83. Cai H, Babic I, Wei X, Huang J and Witte ON. Invasive prostate carcinoma driven by c-Src

and androgen receptor synergy. Cancer Research 2011;71:862-72. PMID: 21135112

84. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, Huang J, and Witte

ON. Methods for the purification and direct transformation of epithelial progenitor cells from

primary human prostate. Nature Protocol. 2011; 6:656-67. PMID: 21527922

85. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO,

MacLennan GT, Montironi R, and Cheng L. ERG-TMPRSS2 Rearrangement is Shared by

Concurrent Prostatic Adenocarcinoma and Prostatic Small Cell Carcinoma and Absent in

Small Cell Carcinoma of the Urinary Bladder: Further Evidence Supporting Monoclonal

Origin. Mod Pathol, 2011 24:1120-7. PMID: 21499238

86. Wang S, Liu K, Liu J, Yu Z T-F, Xu X, Zhao L, Lee T, Lee EK, Reiss J, Lee Y-K, Chung

LWK, Huang J, Rettig M, Seligson D, Duraiswamy KN, Shen C K-F, Tseng H-R. Highly

Efficient Capture of Circulating Tumor Cells Using Nanostructured Silicon Substrates with

Integrated Chaotic Micromixers. Angew Chem Int Ed Engl. 2011; 50:2857 (PMID:

21381170)

87. Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, Magyar CE, Huang J, Chai TC, Qiu S, Qiu

Y. Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor

Prognosis in Patients with Cystectomy. PLoS One. 2011;6:e17778. PMID: 21408190

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yang%20G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rosen%20DG%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Liu%20G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yang%20F%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Guo%20X%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xiao%20X%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xue%20F%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mercado-Uribe%20I%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Huang%20J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lin%20SH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lin%20SH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mills%20GB%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Liu%20J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed/20855612


88. Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M,

Montironi R, Lopez-Beltran A: The landscape of EGFR pathways and personalized

management of nonsmall cell lung cancer. Future Oncology 2011; 7: 519-41. PMID:

21463141

89. Tai S, Sun Y, Squires JM, Zhang H, Oh K, Liang C-Z and Huang J. PC3 is a Cell Line

Characteristic of Prostatic Small Cell Carcinoma. Prostate. 2011; 71:1668-79 PMID:

21432867

90. Natarajan S, Marks LS, Margolis D, Huang J, Macairan ML, Lieu P and Fenster A. Clinical

application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011; 29: 334-42.

PMID: 21555104

91. Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA and Xu H. High Grade

Neuroendocrine Carcinomas of the Lung Highly Express EZH2 but Carcinoids Do Not.

Hum Pathol 2011; 42:867-72. PMID: 21292308

92. Sun Y, Perera J, Rubin BP, Huang J. SYT-SSX1 (Synovial Sarcoma Translocated) regulates

PIASy to cause overexpression of NCOA3. J Biol Chem. 2011; 286:18623-32. PMID:

21454665

93. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast

T, Wheeler TM, Srigley JR, Delahunt B, Egevad L; ISUP Prostate Cancer Group.

International Society of Urological Pathology (ISUP) Consensus Conference on Handling

and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling.

Mod Pathol. 2011; 24: 6-15. PMID: 20834234

94. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R,

Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group. International

Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of

Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer

volume. Mod Pathol. 2011; 24: 16-25. PMID: 20818340

95. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH,

Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA; ISUP Prostate Cancer

Group. International Society of Urological Pathology (ISUP) Consensus Conference on

Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic

extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011; 24:26-

38. PMID: 20802467

96. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der

Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; ISUP Prostate Cancer Group

International Society of Urological Pathology (ISUP) Consensus Conference on Handling

and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and

lymph nodes. Mod Pathol. 2011; 24:39-47. PMID: 20818343

97. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R,

Wheeler TM, Delahunt B, Egevad L, Epstein JI; ISUP Prostate Cancer Group. International

Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of

Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011;

24: 48-57. PMID: 20729812

98. Cheng L, Zhang S, Huang J, Li N and Na Y. A critical evaluation of the current histological

grading system for non-invasive papillary urothelial carcinoma. Chin. J. Urol. 2011; 32:427-

431
















99. Mulholland DJ, Tran LM Li Y, Cai H, Morim A, Wang W, Plaisier S, Garraway IP, Huang

J, Graeber TG, Wu H. Cell Autonomous Role of PTEN in Regulating Castration-Resistant

Prostate Cancer Growth. Cancer Cell. 2011; 19:792-804. PMID: 21620777

100. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, Zong Y, Degendt K,

Verhoeven G, Huang J, Witte ON. Role of autonomous androgen receptor signaling in

prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl

Acad Sci U S A. 2011; 108:7962-7. PMID: 21518863

101. Goldstein AS and Huang J. Do neuroendocrine cells come up large in small cell lung

cancer? Cell Cycle. 2011;10:3627. PMID: 22024918

102. Tan N, Margolis DJA, McClure TD, Finley DS, Reiter RE, Huang J, Raman SS. Radical

prostatectomy: value of prostate MRI in surgical planning. Abdom Imaging, 2011; 37:664-

74. PMID: 2199356

103. Finley DS, Margolis D, Raman SS, Ellingson BM, Natarajan S, Tan N, Huang J, Reiter

RE. Fine-tuning robot-assisted radical prostatectomy planning with MRI. Urol Oncol. 2013;

31:766-75. PMID: 21906964

104. Huang L, Schauer IG, Zhang J, Mercado-Uribe I, Deavers MT, Huang J, Liu J. The

oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian

cancer. Int J Clin Exp Pathol. 2011;4:644-50. PMID: 22076164

105. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang

H, Komisopoulou E, Huang J, Graeber TG, Witte ON. Oncogene-specific activation of

tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A.

2012;109:1643-1648. PMID: 22307624

106. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H.

Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated

from prostate cancer stem/progenitor cells. Cancer Res. 2012; 72:1878-89. PMID: 22350410

107. Chen H, Sun Y, Wu C, Magyar E, Li X, Cheng6 L, Yao JL, Shen S, Osunkoya AO,

Liang C and Huang J. Pathogenesis of Prostatic Small Cell Carcinoma Involves the

Inactivation of the P53 Pathway. Endocr Relat Cancer. 2012;19:321-331. PMID: 22389383

108. Ding B, Sun Y, Huang J. Overexpression of SKI oncoprotein leads to P53 degradation

through regulation of MDM2 sumoylation. J Biol Chem. 2012;287:14621-30.PMID:

22411991

109. Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C and

Huang J. Combination of Rad001 (Everolimus) and Propachlor synergistically induces

apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012;

11:1320-31; PMID: 22491797

110. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS,

Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG. The PSA(-/lo) Prostate

Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that

Resist Castration. Cell Stem Cell. 2012;10:556-69.

111. Liu N, Tai S, Ding B, Thor RK, Bhuta S, Sun Y and Huang J. Arsenic trioxide

synergizes with Everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through

increased autophagy and apoptosis Endocr Relat Cancer. 2012; 19:711-23. PMID:

22919067

112. Paik DY, Janzen DM, Schafenacker AM, Velasco VS, Shung MS, Cheng D, Huang J,

Witte ON, Memarzadeh S. Stem-Like Epithelial Cells are Concentrated in the Distal End of









the Fallopian Tube: A Site for Injury and Serous Cancer Initiation. Stem Cells. 2012;

30:2487-97. PMID: 22911892

113. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated

proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin

signaling. Genes Dev. 2012; 26:2271-85. PMID: 23070813

114. Sonn GA, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Marks

LS. Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic

Resonance Ultrasound Fusion Device. J Urol. 2012; 189:86-92. PMID: 23158413

115. Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK,

Witte ON. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via

paracrine Wnt signaling. Proc Natl Acad Sci U S A. 2012; 109:E3395-404. PMID:

23184966

116. Huang J, Wang JK, and Sun Y. Molecular Pathology of Prostate Cancer Revealed by

Next Generation Sequencing: Opportunities for Genome-Based Personalized Therapy. Curr

Opin Urol. 2013; 23:189-93. PMID: 23385974

117. Li Z, Chen CJ, Wang JK, Hsia E, Squires J, Sun Y and Huang J. Neuroendocrine

Differentiation of Prostate Cancer. Asian Journal of Andrology 2013; 15:328-32. PMID:

23503426

118. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R6, Simons BW, Ward

JM , Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A and Cardiff RD. Animal

models of human prostate cancer: The Consensus Report of the New York Meeting of the

Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer

Research 2013; 73:2718-2736. PMID: 23610450

119. An J, Liu H, Magyar CE, Guo Y, Veena MS, Srivatsan ES, Huang J, Rettig MB.

Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma.

Cancer Res. 2013;73:1374-85 PMID: 23393199

120. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ,

Reiter RE, Marks LS. Value of Targeted Prostate Biopsy Using Magnetic Resonance-

Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific

Antigen. Eur Urol. 2013 Mar 17. [Epub ahead of print] PMID: 23523537

121. Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-

Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, MacLennan GT, Baldridge

LA, Compérat E, Cheng L: Frequent TMPRSS2-ERG rearrangement in prostatic small cell

carcinoma detected by fluorescence in situ hybridization: the superiority of FISH over ERG

immunohistochemistry. Hum Pathol 2013; 44:2227-2233.

122. Cheng L, Wang X, Teng, X, Huang J and Na Y. Recent development in the staging of

bladder urothelial carcinoma. Chin J. Urol. 2013; 34: 328-332

123. Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G.

Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of

pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell

lines. Prostate. 2013 Sep;73(13):1378-90. PMID: 23728788

124. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, Gao X, Liu

Z, Hou J, Huang J, Sun Y. Long non-coding RNA metastasis associated in lung

adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for

diagnosing prostate cancer. Eur J Cancer. 2013; 49:2949-59. PMID: 23726266






125. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH,

Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR,

Shao C, Posadas EM. NanoVelcro Chip for CTC enumeration in prostate cancer patients.

Methods. 2013 Jun 28. doi:pii: S1046-2023(13)00220-X. 10.1016/j.ymeth.2013.06.019.

[Epub ahead of print] PMID: 23816790

126. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, Xu C, Huang

J, Zhao Y, Sun Y. Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target

for Castration-Resistant Prostate Cancer. J Urol. 2013 Jul 8. doi:pii: S0022-5347(13)04856-8.

10.1016/j.juro.2013.07.001. [Epub ahead of print] PMID: 23845456

127. Zong Y, Goldstein AS, Huang J. The molecular basis for ethnic variation and

histological subtype differences in prostate cancer. Sci China Life Sci. 2013; 56:780-7.

PMID: 23852643

128. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H,

Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. The International

Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J

Surg Pathol. 2013; 37:1469-89. PMID: 24025519

129. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J,

Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP

Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading

system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;

37:1505-17. PMID: 24025521

130. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon

DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel.

Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013; 37:1518-31.

PMID: 24025522

131. Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Brantley

Thrasher J, Li B. Cav1.3 channel α1D protein is overexpressed and modulates androgen

receptor transactivation in prostate cancers. Urol Oncol. 2013 Sep 17. [Epub ahead of print]

PMID: 24054868

132. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, Elashoff D, Freedland SJ,

Rettig M, Aronson WJ. Association between tumor-associated macrophage infiltration, high

grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer

Res. 2013; 3:523-9. PMID: 24224130

133. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J,

Pienta KJ, Graeber TG, Witte ON. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier

CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Proc Natl Acad Sci U S A.

110:E4762-9. PMID: 24248375

134. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn

DB, Huang J, Witte ON, Goldstein AS. Prostate cancer originating in basal cells progresses

to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A. 2013;

110:20111-6. PMID: 24282295

135. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky

AD, Qiu Y. Androgen receptor splice variant AR3 promotes prostate cancer via modulating

expression of autocrine/paracrine factors. J Biol Chem. 2013 Dec 2. [Epub ahead of print]

PMID: 24297183

136. Lusch A, Leary R, Heidari E, Liss MA, Okhunov Z, De Lorca AP, Huang J,

Wikenheiser J, Landman J. Intrarenal and Extrarenal Autonomic Nervous System Redefined.

J Urol. 2013; 191:1060-5. PMID: 24333240

137. Chen Y, Nowak I, Huang J, Keng PC, Sun H, Xu H, Wei G, Lee SO. Erk/MAP Kinase

Signaling Pathway and Neuroendocrine Differentiation of Non-Small-Cell Lung Cancer. J

Thorac Oncol. 2014; 9:50-8. PMID: 24346093

138. Le JD, Huang J, and Marks LS. Targeted prostate biopsy: Value of multi-parametric

magnetic resonance imaging in detection of localized cancer. Asian Journal of Andrology

(in press)

139. Chamie K, Sonn GA, Finley DS, Tan N, Margolis DJ, Raman SS, Natarajan S, Huang J,

Reiter RE. The role of magnetic resonance imaging in delineating clinically significant

prostate cancer. Urology. 2014 Feb;83(2):369-75. doi: 10.1016/j.urology.2013.09.045.

PMID: 24468511 [PubMed - in process]

140. Hu J, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey

FJ, Marks LS. Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the

Epstein Criteria Still Apply? J Urol. 2014 Feb 7. pii: S0022-5347(14)00250-X. doi:


141. Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS,

Pantuck AJ. Poor prognosis and advanced clinicopathological features of clear cell renal cell

carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia

inducible factor-2α. Eur J Cancer. 2014 Feb 21. pii: S0959-8049(14)00105-1. doi:

10.1016/j.ejca.2014.01.031. [Epub ahead of print] PMID: 24565854

142. Le JD, Huang J, Marks LS. Targeted prostate biopsy: value of multiparametric magnetic

resonance imaging in detection of localized cancer. Asian J Androl. 2014 Feb 28. doi:

10.4103/1008-682X.122864. [Epub ahead of print] PMID: 24589455

143. Lipianskaya J, Cohen A, Chen CJ, Hsia E, Squires J, Li Z, Zhang Y, Li W, Chen X, Xu

H, Huang J. Androgen-deprivation therapy-induced aggressive prostate cancer with

neuroendocrine differentiation. Asian J Androl. 2014; 16:541-4. PMID: 24589459

144. Beltran H, Tomlins SA, Aparicio AM, Arora VK, Rickman DS, Ayala GE, Huang J,

True LD, Gleave ME, Soule HR, Logothetis CJ, Rubin MA. Aggressive Variants of

Castration Resistant Prostate Cancer. Clin Cancer Res. 2014 Apr 11. [Epub ahead of print]

PMID: 24727321

145. Wang L, Williamson SR, Zhang S, Huang J, Montironi R, Davison DD, Wang M, Yao

JL, Lopez-Beltran A, Osunkoya AO, Maclennan GT, Baldridge LA, Du X, Cheng L.

Increased androgen receptor gene copy number is associated with TMPRSS2-ERG

rearrangement in prostatic small cell carcinoma. Mol Carcinog. 2014 Apr 29. doi:

10.1002/mc.22162. [Epub ahead of print] PMID: 24777847

146. Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA, Natarajan S, Dorey FJ,

Huang J, Margolis DJ, Reiter RE, Marks LS. MRI-ultrasound fusion biopsy for prediction of

final prostate pathology. J Urol. 2014 Apr 30. pii: S0022-5347(14)03509-5. doi:


147. Wang JG, Huang J, Chin AI. RARP in high-risk prostate cancer: use of multi-parametric

MRI and nerve sparing techniques. Asian J Androl. 2014 Jun 20. [Epub ahead of print]

PMID: 24969055

148. Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang

L, Hynes P, Hsieh YY, Liu YN, Huang J, Kelly K. Loss of EGFR signaling regulated miR-

203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

Oncotarget. 2014 Jun 15;5(11):3770-84. PMID: 25004126

149. Priester A, Natarajan S, Le JD, Garritano J, Radosavcev B, Grundfest W, Margolis DJA,

Marks LS and Huang J. A system for evaluating magnetic resonance imaging of prostate

cancer using patient-specific 3D printed molds. Am J Clin Exp Urol 2014; 2:127-35

150. Sonn GA, Filson CP, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J,

Dorey FJ, Reiter RE, Marks LS. Initial experience with electronic tracking of specific tumor

sites in men undergoing active surveillance of prostate cancer. Urol Oncol. 2014 [Epub ahead

of print] PMID: 25027689

151. Drake JM, Huang J. PIP5K1α inhibition as a therapeutic strategy for prostate cancer. Proc

Natl Acad Sci U S A. 2014 Aug 12. pii: 201413363. [Epub ahead of print] PMID: 25118275

152. Xu X, Lipianskaya J, Huang J. Fasting times in serum PSA assay. Asian J Androl. 2014

Jun 24. doi: 10.4103/1008-682X.125405. [Epub ahead of print] PMID: 25130470

153. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman

SS, Reiter RE. Multifocality and Prostate Cancer Detection by Multiparametric Magnetic

Resonance Imaging: Correlation with Whole-mount Histopathology. Eur Urol. 2014 Sep 22.

pii: S0302-2838(14)00891-4. doi: 10.1016/j.eururo.2014.08.079. [Epub ahead of print].

PMID: 25257029

154. Priester A, Natarajan S, Le JD, Garritano J, Radosavcev B, Grundfest W, Margolis DJ,

Marks LS, Huang J. A system for evaluating magnetic resonance imaging of prostate cancer

using patient-specific 3D printed molds. Am J Clin Exp Urol. 2014 Jul 12;2(2):127-35.

eCollection 2014. PMID: 25374914

155. Li Y, Liang C, Huang J. Serum lipid profiles and aggressive prostate cancer. Asian J

Androl [Epub ahead of print]

156. Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C, Huang J. p53 Mutation

Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell

Neuroendocrine Carcinoma. Mol Cancer Res. 2014 Dec 15. pii: molcanres.0277.2014.


157. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C,

Chen J, Zynger DL, Yan PS, Huang J, Nephew KP, Huang TH, Lin S, Clinton SK, Li W, Jin

VX, Wang Q. Agonist and antagonist switch DNA motifs recognized by human androgen

receptor in prostate cancer. EMBO J. 2014 Dec 22. pii: e201490306. [Epub ahead of print]

PMID: 25535248

158. Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK. Elevated circulating

tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine

differentiation in castration resistant prostate cancer. Prostate. 2015 Jan 5. doi:

10.1002/pros.22945. [Epub ahead of print] PMID: 25560638

159. Escamilla J, Liu C, Priceman SJ, Sung JL, Pouliot F, Magyar C, Jiang Z, Xu J, West B,

Bollag G, Fradet, Lacombe L, Jung ME, Huang J, Wu L. CSF1 Receptor Targeting In

Prostate Cancer Reverses Macrophage-Mediated Resistance To Androgen Blockade

Therapy. Cancer Res (In press)

160. Peek EM, Song W, Zhang H, Huang J, Chin AI. Loss of MyD88 leads to more

aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. Prostate.

2015 Jan 16. doi: 10.1002/pros.22932. [Epub ahead of print] PMID: 25597486

161. Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD,

Pomerantz M, Oh WK. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have








Significantly Worse Outcomes Compared with Gleason 8 Disease. J Urol. 2015 Jan 23.


Invited Lectures and Presentations:

Invited by Academic Institutions:

1. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine.

Honors Program, Postgraduate School of New York University School of Medicine, 1990

2. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding

protein. Sacklar Institute of Biomolecular Medicine Research Seminar, New York University

School of Medicine, 1991


protein. Special Seminar, Howard Hughes Medical Institute, University of California School

of Medicine at San Francisco, 1992


protein. Howard Hughes Medical Institute, University of Washington at Seattle, 1992

5. Molecular pathology of lung cancer: Impact on prognosis and management. Grand Rounds,

Department of Pathology, New York University School of Medicine, May 1998

6. Molecular pathology of lung cancer: Impact on prognosis and management. Combined Grand

Rounds, Departments of Pathology, Cornell University School of Medicine and Memorial

Sloan-Kettering Cancer Center, November 4, 1999

7. Molecular pathology of lung cancer: Impact on prognosis and management. Department of

Pathology, Temple University School of Medicine, December, 1999

8. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated

tumors. Cancer Research Institute, Chinese Academy of Medicine, Beijing, China,

November, 2001


tumors. Beijing University School of Medicine, Beijing, China, November, 2001


tumors. Shanxi University School of Medicine, Taiyuan, China, November, 2001


tumors. Dalian University School of Medicine, Dalian, China, November, 2001

12. Contemporary classification of renal tumors. Dalian University School of Medicine, Dalian,

China, November, 2001

13. Molecular Pathology of Lung Cancer. Department of Pathology, University of Chicago,

November, 2002

14. Pathology of prostate cancer. Chaoyang Hospital, Capitol Medical University, Beijing,

September 2003

15. Pathology of prostate cancer. The General Hospital of the Army, Beijing, September 2003

16. Neuroendocrine differentiation of prostate cancer. Roswell Park Cancer Center, July, 2004

17. Neuroendocrine differentiation of prostate cancer. Department of Urology, University of

Rochester Medical Center, July, 2005

18. Neuroendocrine differentiation of prostate cancer. Department of Pathology, University of

Rochester Medical Center, April, 2006

19. Neuroendocrine differentiation of prostate cancer. Department of Pathology, Emory

University School of Medicine, May, 2006

20. Grand Round Speaker, Department of Pathology, New York University School of Medicine,

March, 2007 (Neuroendocrine differentiation of prostate cancer).

21. Neuroendocrine differentiation of prostate cancer. Department of Pathology, School of

Medicine, University of California at Los Angeles, June 2007

22. Departmental Seminar Speaker, Department of Medicinal Chemistry and Molecular

Pharmacology, School of Pharmacy, Purdue University, September 2007 (Neuroendocrine

differentiation of prostate cancer).

23. Departmental Seminar Speaker, Department of Pharmacology & Experimental Therapeutics,

University of Maryland School of Medicine, June 2008 (Neuroendocrine cells in prostate

cancer).

24. Grand round speaker, Department of Pathology, University of Nebraska, Omaha, NE, May

2010 (Neuroendocrine cells in prostate cancer)

25. Grand round speaker, Brady Urology Institute, Johns Hopkins University Hospital, Baltimore,

MD, Dec 2010 (Neuroendocrine Differentiation in Prostate Cancer).

26. Neuroendocrine Differentiation in Prostate Cancer, UCLA Specialized Program of Research

Excellence (SPORE) in Prostate Cancer, April 2011

27. Pathology of Prostate Cancer, Wu Jie-Ping Urologic Center, Beijing University, May 2011

28. Neuroendocrine Differentiation in Prostate Cancer, Anhui Medical University, May 2011

29. Immunohistochemistry in the Differential Diagnosis of Genitourinary Tumors, Anhui

Medical University, May 2011

30. Neuroendocrine Differentiation in Prostate Cancer, Department of Urology, Massachusetts

General Hospital of Harvard University, June 2011

31. Immunohistochemistry in the Diagnosis and Differential Diagnosis of Genitourinary Tumors.

Adicon Clinical Laboratories Inc., Hangzhou, China, November 1, 2011

32. Medical Education in the United States, Anhui Medical University, Hefei, China. November

8, 2011

33. Medical-Legal Issues in the United States, the First Affiliated Hospital of Anhui medical

University, Hefei, China, November 10, 2011

34. Tissue recombination technology in cancer research, Cancer Center, Zhejiang University

School of Medicine, Hangzhou, July 2012

35. Neuroendocrine differentiation in prostate cancer, Department of Pathology, Yale University

School of Medicine, August 2012

36. Neuroendocrine Differentiation in Prostate Cancer, Department of Pathology, University of

California at Irvine, Irvine, CA, September 21, 2012

37. Neuroendocrine Differentiation in Prostate Cancer, Department of Urology, Tongji Hospital,

Huazhong University of Science and Technology, Wuhan, China, May 2013

38. Neuroendocrine Differentiation in Prostate Cancer, Department of Urology, West China

Hospital of Sichuan University, Chengdu, China, June 2013

39. Recent progress in prostate cancer. Wuxi Second People's Hospital, Wuxi, China, November

2013

40. Recent progress in prostate cancer. National Center of Biomedical Analysis (NCBA),

Beijing, China, November 2013

41. Therapy-induced aggressive variants of prostate cancer with neuroendocrine differentiation. .

Cancer Biology Work-In-Progress Seminar Series, Samuel Oschin Comprehensive Cancer

Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, May 2014

42. Pathology of prostate cancer. Pathology Conference, Kaiser Permanente Pathology

Department, Los Angeles, CA. May 2014

43. Neuroendocrine differentiation in prostate cancer. Grand Round. Department of Pathology,

Loma Linda University School of Medicine. Loma Linda, CA. June 2014

44. Aggressive phenotype of prostate cancer induced by conventional and modern hormonal

therapy. Huanxi Hospital of Sichuan University, Chengdu, China, August 2014

45. Aggressive phenotype of prostate cancer induced by conventional and modern hormonal

therapy. Eastern China Normal University, Shanghai, China, September 2014

Invited by Local, National and International Conferences

1. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine.

Cold Spring Harbor Meeting: Translational Control. 1989; Cold Spring Harbor, New York


protein. American Society of Virology Annual Meeting, 1991; Fort Collings, Colorado

3. Molecular analysis of synchronous and metachronous tumors of the lung: Impact on

management and prognosis. XXI International Congress of the International Academy of

Pathology and 13th World Congress of Academic and Environmental Pathology, 1998; Nice,

France

4. Fibrolamellar carcinoma of the liver: Immunohistochemical study of 11 cases and

comparison with conventional hepatocellular carcinoma . 89th Annual Meeting, United States

and Canada Academy of Pathology, New Orleans, LA, 2000

5. Prognostic significance of neuroendocrine phenotype expression in human prostate

carcinoma. International Symposium on Prostate Cancer: Novel Strategies for a New

Disease. Turin, Italy, September, 2003

6. Neuroendocrine differentiation of prostate cancer. The 4th Asia-Pacific IAP Congress,

August 23 – 26, 2005 Beijing, China

7. Plenary Speaker, 13th Annual Meeting of the Chinese Urological Society, Shenyang, China,

October 2006 (Recent advances in the pathology of urological tumors).

8. Invited participant, 11th Prouts Neck Meeting on Prostate Cancer "Emerging Strategies in

Prostate Cancer Therapy", Prouts Neck, Maine, Nov 2-5, 2006

9. Plenary Speaker, Annual Meeting of the Chinese Society of Pathology, Chengdu, China,

April 2007 (Immunohistochemistry in the differential diagnosis of undifferentiated tumors)

10. Invited Speaker and Session Co-Chair, Nanjing International Symposium of New Frontiers in

Cancer Research, Nanjing, China, November 2007 (Neuroendocrine differentiation of

prostate cancer).

11. Plenary Speaker, 14th Annual Meeting of the Chinese Urological Society, Xiamen, China,

November 2007 (Neuroendocrine differentiation of prostate cancer).

12. Plenary Speaker, 15th Annual Meeting of the Chinese Urological Association, Kunming,

China, September 2008 (Neuroendocrine cells in prostate cancer).

13. Plenary Speaker, 11th Mid-east Association of the Urology of China, Huangshan, China,

June 2009

14. Invited Speaker, 16th Annual Meeting of the Chinese Urological Association, Chengdu,

China, September 2009 (Recent advances in prostate cancer research).

15. The Function of Neuroendocrine Cells in Prostate Cancer. Prostate Cancer Foundation

Scientific Retreat. Reno, NV, Sept 2009

16. The Function of Neuroendocrine Cells in Prostate Cancer. NCI Translational Science

Meeting, Tyson Corer, VA. Nov 2009

17. Plenary speaker, 2010 Annual Scientific Meeting, the Association of Chinese American

Physicians, New York, NY, May 2010

18. Plenary Speaker, Anhui Province Pathologists Association Meeting, China, Oct 2010

(Pathologic Diagnosis of Bladder Cancer)

19. Plenary Speaker, Anhui Province Urologists Association Meeting, China, Oct 2010 (Recent

progress in prostate cancer and new therapies)

20. NCI Special Conference: Androgen Receptor in Prostate Cancer: Translating Biology into

Clinical Practice. Arlington, VA. December 6-7, 2010 (Models of Tumor Development (e.g.

cancer stem cells))

21. P53 Pathway is Involved in the Pathogenesis of Small Cell Carcinoma of the Prostate. The

second Innovative Minds in Prostate Cancer Today (IMPaCT) conference. Department of

Defense Prostate Cancer Research Program (PCRP). Orlando, FL, March 2011

22. Individualized treatment for cancer. Invited Speaker. Technical Symposium of 49th

anniversary of the Chinese-American Engineers and Scientists Association of Southern

California (CESASC). San Gabriel, CA, April 2011

23. Tissue recombination technology in the study of tumor initiation cells for prostate cancer.

Invited Speaker. Steering Committee Meeting, Intestinal Stem Cell Consortium (ISCC).

Stowers Institute, Kansas City, Missouri, May 2011

24. Diagnostic Usage of Immunohistochemistry in Genitourinary Pathology. 4th Biannual MD

Anderson Cancer Center-Fudan University Pathology Conference. May 14-15, 2011.

Shanghai, China.

25. International session moderator, 18th Annual Meeting of Chinese Urological Association,

October 28-30, 2011. Nanjing, China

26. Speaker for Cancer Committee, Zhejiang University-UCLA Joint Center for Research,

Hangzhou, China. November 4, 2011

27. Recent Progress in Prostate cancer, Continuing Medical Education Conference of Chinese

Urological Association, Huangshan, China, November 12, 2011

28. Panel Member, NCI-MMHCC Pathology Consensus Report Workshop, April 17-18, 2012,

New York, NY

29. Pathology of prostate cancer. 2012 Hangzhou International Pathology Symposium, Hangzhou,

China, April, 2012 30. Pathology of testicular tumors. 2012 Hangzhou International Pathology Symposium, Hangzhou,

China, April, 2012 31. Small cell carcinoma of the prostate: Molecular mechanisms of carcinogenesis. The 7th

Forum of Prostate Disease. Shanghai, China, June 2012.

32. International session moderator, 19th Annual Meeting of Chinese Urological Association,

November, 2012. Guangzhou, China

33. Application of Immunohistochemistry The annual Hangzhou Symposium on the recent

development of molecular diagnosis and treatment of tumors. Hangzhou, China, April 19-21,

2013

34. Neuroendocrine Differentiation in Prostate Cancer, International forum on translational

medicine of Urology, Tianjin, China, April 26-28, 2013

35. Neuroendocrine Differentiation in Prostate Cancer, the 2nd Annual PCF China Scientific

Symposium, Shanghai, China, May 2013

36. Neuroendocrine Differentiation in Prostate Cancer, Annual Urology Conference, the 2nd

Affiliated Hospital of Zhejiang University, Hangzhou, China, May 2013

37. Genitourinary Pathology Case discussion, 2nd Huaxia Pathology Forum, Guilin, China, June

2013

38. Targeted biopsy of prostate cancer, The 7th Annual Forum of Prostate Diseases, Shanghai,

China, July 27, 2013

39. Challenges in the Diagnosis of Small Cell Neuroendocrine Carcinoma, The 7th Annual

Forum of Prostate Diseases, Shanghai, China, July 27, 2013

40. Pathology and Biology of Neuroendocrine Prostate Cancer, Pathology Workshop for t-NEPC

organized by Prostate Cancer Foundation. New York, NY. July 31, 2013

41. Recent progress in prostate cancer. Soochou University Annual Translational Medicine

Meeting, Suzhou, China, November 2013

42. Prostate Cancer Stem Cells, Annual Jingmeng Stem Cell Conference, Beijing, China, Feb 15,

2014

43. Aggressive variants of castration-resistant prostate cancer. The Annual Meeting of the Basic

Science Division, Chinese urologic Association, April 26, 2014.

44. Neuroendocrine phenotype of therapy-resistant prostate cancer. Society for Basic Urologic

Research (SBUR) Symposium. Dallas, TX. Nov 13,, 2014.

45. Immunohistochemistry in the differential diagnosis of genitourinary tumors. Pathology

Symposium organized by Zhejiang Province Quality Control Center, Hangzhou, China, May

2014

46. Pathology of prostate cancer. Pathology Symposium organized by Zhejiang Province Quality

Control Center, Hangzhou, China. May 2014.

47. Standardized pathology reporting of prostate biopsy and prostatectomy specimens in the

modern era. 8th Annual Forum of Prostate Diseases co-sponsored by Prostate Cancer

Foundation and Shanghai Changhai Hospital, September 2014

48. Targeted biopsy of prostate cancer. 8th Annual Forum of Prostate Diseases co-sponsored by

Prostate Cancer Foundation and Shanghai Changhai Hospital, September 2014

49. Advancing pathology diagnosis of urologic tumors for better patient care.. International

Forum of Urologic Tumors, Shanghai Cancer Hospital of Fudan University, November 2014

50. Therapy-induced changes in metastatic prostate cancer. Jingmeng Stem Cell International

Coference, Beijing, China, March 2015

Presentations in conferences (platform and poster presentations)

1. Huang J, Wistuba I, Behrens C, Gazdar AF, Kornacki S and Jagirdar J. Utilization of

microdissection, PCR and LOH assay in the study of combined and collision tumors. 86th

Annual Meeting, United States and Canada Academy of Pathology, 1997; Orlando, Florida

2. Huang J, Melamed M. Dysplastic (“in-situ”) lesions in multifocal renal oncocytomas. 89th

Annual Meeting, United States and Canada Academy of Pathology, 1999; San Francisco,

California

3. Vargas R, Bourn P and Huang J. Immunostaining for Calponin can completement 34E12

in prostatic biopsy. 90th Annual Meeting, United States and Canada Academy of Pathology,

2001; Atlanta, Georgia

4. Li R, Ni J, Yeh S, di Sant’agnese and Huang J. Cell block array: Development of a novel

technique for the study of cultured cells by immunohistochemistry. 92th Annual Meeting,

United States and Canada Academy of Pathology, 2003; Washington, D.C.

5. Li R, di Sant’agnese and Huang J. Frequent expression of human carcinoma-associated

antigen (HCA), a mucin-type glycoprotein, by cells of prostatic carcinoma 92th Annual

Meeting, United States and Canada Academy of Pathology, 2003; Washington, D.C.

6. H Li, L Zhang, I Ding, J Huang, PA diSant Agnese, H Lou, JY Lei. Over-Expression of

Decoy Receptor 3 in Precancerous Lesions and Adenocarcinoma of the Esophagus. Mod

Path. 2003. 17: S1; 121A. Presented at 94th Annual Meeting of the United States and

Canadian Academy of Pathology, Vancouver, BC, March 2004.

7. S Liang, J Huang, PA Bourne, PA diSant Agnese, J Yao, JY Lei. Over-Expression of

Human Carcinoma-Associated Antigen in Precancerous Lesions and Adenocarcinoma of the

Esophagus. Mod Path. 2003. 17: S1; 121A-122A. Presented at 94th Annual Meeting of the

United States and Canadian Academy of Pathology, Vancouver, BC, March 2004.

8. Yao JL, Alvarez VA, Bourne PA, Lei JY, di Sant’Agnese PA, and Huang J. Neuroendocrine

Cells Correlate with Proliferation Centers in Benign Nodular Prostatic Hyperplasia. Mod


Canadian Academy of Pathology, Vancouver, BC, and March 2004.

9. Yao JL, Li R, Bourne PA, Lei JY, di Sant’Agnese PA, and Huang J. Overexpression of

Human Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder. Mod



10. Yao JL, McClaskey JH, Quinn A, Bourne PA, Lei JY, di Sant Agnese PA and Huang J.

Mucin Expression in Benign and Neoplastic Prostate Using Tissue Microarrays. Mod Path.

2003. 17: S1; 185A-186-A. Presented at 94th Annual Meeting of the United States and


11. JY Lei, PA Bourne, J Huang, PA diSant Agnese.Thyroid Transcription Factor-1 as a Useful

Marker in the Differential Diagnosis of Hepatocellular Carcinoma from Cholangiocarcinoma

and Metastatic Carcinoma in the Liver. Mod Path. 2003. 17: S1; 306A. Presented at 94th

Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC,

March 2004.

12. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant’Agnese PA and Reeder JE.

Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non-

neuroendocrine compartments of prostate cancer. 2005 AACR Annual Meeting, Anaheim,

California, April 2004 13. Yao JL, Bourne PA, Lei JY, Yang X, Tickoo SK, Liu Z, Huang J and Di Sant Agnese PA.

Expression of Novel Markers in Small Cell Carcinoma of the Prostate: Possible Therapeutic

Targets. Mod Path. 2005. 18: S1; 173A. 95th Annual Meeting of the United States and

Canadian Academy of Pathology, San Antonio, TX, February 2005.

14. Nigwekar P, Yao JL, di Sant'Agnese PA, Mayer RD, Reeder JE, Huang J. Overexpression

of Heme Oxygenase-1 in Prostate Cancer. Presented at the 95th Annual Meeting of the

United States and Canadian Academy of Pathology, Atlanta, GA, February 2006.

15. Simon R, Bourne PA, di Sant’Agneses PA, Huang J and Yao JL. Mini Chromosome

Maintenance Protein 6 Expression in the Prostate: a Tissue Microarray Analysis. Presented at

the 95th Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta,

GA, February 2006.

16. Golijanin DJ, Wood RW, Madeb RR, Silvers CR, Yao JL, Huang J, Messing EM, Reeder

JE, Joseph JV. Intraoperative Visualization of Cavernous Nerves Using Near Infrared

Fluorescence of Indocyanine Green in the Rat. Presented at the 101st Annual Meeting of the

American Urological Association, Atlanta, GA, May 2006.

17. Simon R, di Sant'Agnese PA, Yao JL, Bourne PA, Bohrer KA and Huang J. Prostate Cancer

is Associated with Increased Expression of Nuclear Cyclin D1. Accepted for presentation at

the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San

Diego, CA, March 2007.

18. Li L, Simon R, Spauldin BO, Bourne PA, Yao JL, di Sant'Agnese PA, Xu H and Huang J.

KOC is a Useful Marker for the Classification of Urothelial Neoplasms of the Bladder.

Accepted for presentation at the 96th Annual Meeting of the United States and Canadian

Academy of Pathology, San Diego, CA, March 2007.

19. Li L, Bourne PA, Yao JL, di Sant'Agnese PA, Zhuang Z, Yin C, Wu C and Huang J.

Myosin VI, a Mediator of The P53-Dependent Cell Survival Pathway, is Overexpressed in

Adenocarcinoma of the Prostate. Accepted for presentation at the 96th Annual Meeting of the

United States and Canadian Academy of Pathology, San Diego, CA, March 2007.

20. Lester TR, Kohli M, Quinn A, Reeder JE, Yao JL, di Sant'Agnese PA, Bourne PA and

Huang J. Expression of Thrombin in the Prostate: Implications for Carcinogenesis and

Tumor-associated Hypercoagulation. Accepted for presentation at the 96th Annual Meeting

of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007.

21. Nigwekar P, Lester TR, Yang Q, Bourne PA, Yao JL, di Sant'Agnese PA, Zhai J, Wang H

and Huang J. Overexpression of Human Carcinoma-Associated Antigen (HCA) in

Pancreatic Adenocarcinoma. Accepted for presentation at the 96th Annual Meeting of the

United States and Canadian Academy of Pathology, San Diego, CA, March 2007.

22. Nigwekar P, Wu C, Yao JL, Bourne PA, Li J, Zhuang Z, di Sant'Agnese PA, Walters DC

and Huang J. Nucleophosmin, a Critical Regulator of Cell Proliferation, is Overexpressed in

Prostate Cancer. Accepted for presentation at the 96th Annual Meeting of the United States

and Canadian Academy of Pathology, San Diego, CA, March 2007.

23. Simon RA, Xu H, Bourne PA, Yao JL, Wei J, Liang S, Liu, J, di Sant'Agnese PA, Cheng L,

and Huang J. CD44 is a Useful Marker for Prostatic Small Cell Carcinoma. 97th Annual

Meeting, United States and Canada Academy of Pathology, Denver, CO 2008

24. Wagner DG, Scott G,Yang Q and Huang J. Stem Cell-Associated Markers Are Useful in

Distinguishing Melanoma From Nevi. 98th Annual Meeting, United States and Canada

Academy of Pathology, Boston, MA 2009



cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate Cancer

Foundation Scientific Retreat. Reno, NV, Sept 2009



cell marker, in neuroendocrine tumor cells of human prostate cancer. NCI Translational

Science Meeting, Tyson Corer, VA. Nov 2009

27. Mulholland DJ, Kobayashi N, Johnston M, Sun Z, Morim A, Wu L, Huang J, Wu H.

Cooperativity between Pten loss and K-ras activation in promoting EMT and metastasis in

murine prostate cancer. AACR Special Conference (EMT and Cancer Progression and

Treatment) Arlington, Virginia, 2010

28. Clebanoff JL, Magyar C, Yao JL, di Sant'Agnese PA, Cheng L, Yang Q, Li X and Huang J.

p53 Pathway is Involved in the Pathogenesis of Small Cell Carcinoma of the Prostate. 99th

Annual Meeting, United States and Canada Academy of Pathology, Washington DC, 2010

29. Wagner D, Miller E, Yang Q, Scott G, Rubin BP and Huang J. Stem Cell-Associated

Markers Distinguish Melanoma from Malignant Peripheral Nerve Sheath Tumor. 99th Annual

Meeting, United States and Canada Academy of Pathology, Washington DC, 2010

30. Huss J, Raman S and Huang J. Kidney Biopsy for Tumors: Pathologic Interpretation and

Clinical Significance. 100th Annual Meeting, United States and Canada Academy of

Pathology, San Antonio, TX 2011

31. Miller E, Rettig M, Magyar C and Huang J. Strong and Diffuse Nuclear Staining for

Phospho-c-Jun Distinguishes Clear Cell Renal Cell Carcinoma from its Mimickers. 100th

Annual Meeting, United States and Canada Academy of Pathology, San Antonio, TX 2011

32. Palla B, Zhang H and Huang J. A Novel Method to Procure Fresh Prostate Tissue for Viable

Epithelial Cells. 100th Annual Meeting, United States and Canada Academy of Pathology,

San Antonio, TX 2011

33. Marks L, Natarajan S, Margolis D, Huang J, Kumar D, Narayanan R, Bentley R, Macairan

ML and Lieu P. Artemis: An Office-Based Device For MRI Fusion And Targeted Prostate

Biopsy. American Urologic Association Annual Meeting, Washington DC, May 2011

34. Song G, Natarajan S, Margolis D, Huang J, Dorey F, Macairan ML, Lieu P and Marks LS.

Value of Targeted Biopsy in Detecting Prostate Cancer using an Office-Based MR-US

Fusion Device. American Urologic Association Annual Meeting, Atlanta, GA, May 2012

35. Gollapudi K, Galet C, Grogan T, Zhang H, Huang J, Elashoff D, Gerber L, Freedland S,

Rettig M, Aronson W. Is infiltration of tumor-associated macrophages predictive of

biochemical recurrence after radical prostatectomy? American Urological Association

Annual Meeting, Atlanta, GA May 20, 2012

36. Susan Kerkoutian, Yin Sun, Xinmin Li, Jason Scapa, Jiaoti Huang. Cell Type-Specific

Biomarkers to Predict the Risk of Prostate Cancer in Men with Increased PSA but Negative

Biopsies. United States and Canadian Academy of Pathology Annual Meeting, March 2013,

Baltimore, MD

37. Karow D., White N., Huang J., Reiter R., Mattrey R., Margolis D., Raman S., Dale A.

Improved Conspicuity and Delineation of High-Grade Prostate Tumors Using “Restriction

Spectrum Imaging”: Quantitative Comparison with High B-Value ADC. The International

Society for Magnetic Resonance in Medicine 21st Annual Meeting & Exhibition, 20-26

April 2013, Salt Lake City, Utah, USA

38. Geoffrey Sonn, Shyam Natarajan, Daniel Margolis, Edward Chang, Malu Macairan, Patricia

Lieu, Jiaoti Huang, Frederick Dorey, Leonard Marks. Prospective Evaluation of MRI-

Ultrasound Fusion Biopsy to Diagnose Prostate Cancer in Men with Prior Negative Biopsies.

American Urological Society Annual Meeting, May 2013, San Diego, CA

39. Geoffrey Sonn, Shyam Natarajan, Daniel Margolis, Edward Chang, Malu Macairan, Patricia

Lieu, Jiaoti Huang, Frederick Dorey, Leonard Marks. Targeted Biopsy with MRI-Ultrasound

Fusion. American Urological Society Annual Meeting, May 2013, San Diego, CA

http://ismrm.org/13/

40. Nils Kroeger, David B. Seligson, Sabina Signoretti, Hong Yu, Frederic D. Birkhaeuser, Clara

Magyar, Jiaoti Huang, Joseph Riss, Fairooz F. Kabbinavar, Arie S. Belldegrun, Allan J.

Pantuck. Investigating the association of cytoplasmic and nuclear HIF-2 expression with

cancer specific survival (CSS) in clear cell renal cell carcinoma. American Society of

Clinical Oncology Genitourinary Cancers Symposium, February 2013, Orlando, FL

41. Mitchell Kamrava, Shane Mesko, Robyn Banerjee, Jiaoti Huang, D. Jeffrey Demanes,

Leonard S. Marks. Quantifying the ki-67 heterogeneity profile in prostate cancer. American

Society of Clinical Oncology Genitourinary Cancers Symposium, February 2013, Orlando,

FL

42. Lindsay Ann Schelling; Sean Williamson; Jorge Yao; Shaobo Zhang; Mingsheng Wang;

Huang, Jiaoti; Antonio Lopez; Adeboye Osunkoya; Gregory MacLennan. ERG

Immunohistochemistry in Prostatic Small Cell Carcinoma: Comparison to Fluorescence in

situ Hybridization. United States and Canadian Academy of Pathology Annual Meeting,

March 2013, Baltimore, MD

43. Geoffrey Sonn MD, Edward Chang, Shyam Natarajan, Frederick Dorey, Daniel Margolis ,

Jiaoti Huang, Patricia Lieu, Malu Macairan and Leonard Marks. Impact of MR-Us Fusion

Targeted Confirmatory Biopsy on Patient Selection for Active Surveillance. Society for

Urologic Oncology Annual Meeting, May 2012, Atlanta, GA

44. Boon-Unge K, Yi J, Huang J, Yong WH, Vinters HV, De Jesus J, Vehabedian N, Khanlou N.

Combined Brachyury/CA-IX immunohistochemistry in the diagnosis of notochordal tumors

with atypical features. 89th annual meeting of the American Association of

Neuropathologists. J Neuropathol Exp Neurol. 2013;72(6):540-598.

45. D Margolis, S Raman, E Chang, F Dorey, J Huang, P Lieu, M Macairan, S Natarajan, R

Reiter, G Sonn, L Marks. Detection Rate for Prostate Cancer Using MRI-Ultrasound Fusion

in a Biopsy-Naïve Population. Radiological Society of North America Scientific Assembly

and Annual Meeting, Chicago IL, 1-6 December 2013

46. Mo Z. and Huang J. Expression of androgen receptor splicing variant in benign prostate,

prostatic adenocarcinoma and small cell neuroendocrine carcinoma. United States and

Canada Academy of Pathology annual meeting. San Diego, CA, March 2014

jiaoti huang, m - ucla healthpathology.ucla.edu/workfiles/clinical...

Documents